Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
2 other identifiers
observational
32,379
2 countries
4
Brief Summary
The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients will be ascertained in Finland from previous health surveys and hospital discharge records. Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on family members and blood drawn for DNA isolation. Covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis. The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as NIDDM and intermediate traits like IR....
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 1996
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 1996
CompletedFirst Submitted
Initial submission to the registry
June 19, 2006
CompletedFirst Posted
Study publicly available on registry
June 21, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 22, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 22, 2020
CompletedMay 27, 2020
May 1, 2020
24 years
June 19, 2006
May 22, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
T2D status, quantitative traits measurements
Association testing
ongoing
Study Arms (16)
AADM
Family and Population based individuals
Action-LADA
Population based individuals
D2D 2004
Population based individuals
DIAGEN (Dresden Biobank)
Population based individuals
FINRISK 1987
Population based individuals
FINRISK 2002
Population based individuals; Test DNA
Fusion 1
Affected-sib pair (ASP) families and elderly controls
Fusion 2
275 Replication ASP Families; Trios
Fusion 3
Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
Fusion 4/5
Spouses, Offspring of FUSION 1 and 2 Families
FUSION Finnish Groups
Family and Population based (including METSIM and DR's EXTRA): Tissue samples
Health-2000
Population based individuals
HUNT 2
Population based individuals
METSIM
Population based individuals
Savitaipale
Population based individuals
UEF - Laakso
Monogenic disease individuals and family members
Eligibility Criteria
A large majority of the sample population resides in various parts of Finland and are of Finnish descent. The Finnish population provides an ideal basis for studies of complex genetic diseases such as T2D due to its relative genetic and environmental homogeneity, excellent data sources, and a population strongly supportive of biomedical research. Individuals with or without diabetes (type2 or monogenic forms of diabetes) have been collected.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (4)
Natl Inst for Health & Welfare (THL)
Helsinki, Finland
Research Ethics Committee of Hospital District of Northern Savo
Kuopio, Finland
University of Tromso
Tromsø, Norway
Norwegian U of Science & Technology
Trondheim, Norway
Biospecimen
Blood DNA, Adipose, Muscle, Fibroblast, Serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lori Bonnycastle, Ph.D.
National Human Genome Research Institute (NHGRI)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 19, 2006
First Posted
June 21, 2006
Study Start
June 1, 1996
Primary Completion
May 22, 2020
Study Completion
May 22, 2020
Last Updated
May 27, 2020
Record last verified: 2020-05